These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 10100713)

  • 21. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
    Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rituximab].
    Okamoto R; Maeda Y; Sasaki T
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
    Naparstek E
    Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
    Chu PG; Loera S; Huang Q; Weiss LM
    Am J Clin Pathol; 2006 Oct; 126(4):534-44. PubMed ID: 16938666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C; Castillo J
    Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and characterization of the B-cell marker CD20.
    Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
    Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
    Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
    Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
    Liu YX; Fan DM; Xiong DS; Xu YF; Shao XF; Xu YS; Peng H; Yang M; Qin L; Zhu ZP; Yang CZ
    Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.